FOXO Technologies Announces Issue Notification from USPTO for a Patent Leveraging Machine Learning Approaches to Enable the Commercialization of Epigenetic Biomarkers

Builds on Notices of Allowance Previously Issued by the USPTO for Two Related Patents Leveraging the Same ApproachesMINNEAPOLIS–(BUSINESS WIRE)–FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a chief in the discipline of commercializing epigenetic biomarker know-how, immediately introduced that the United States Patent & Trademark Office (USPTO) has offered an Issue Notification for a key patent using a machine studying mannequin educated to decide a biochemical state and/or medical situation utilizing DNA epigenetic knowledge to allow the commercialization of epigenetic biomarkers. Previously, the USPTO had issued Notices of Allowance to the Company for two associated patents and the Company awaits Issue Notification for the second allowed patent.
The first patent, for which the Company has obtained an Issue Notification, aids in sensible functions of the know-how that embrace producing epigenetic biomarkers. On event, epigenetic knowledge could also be lacking or unreliable as a result of a particular DNA web site could not have been assayed or was unreliably measured. The patent permits the use of machine studying estimators to “fill in” the lacking or unreliable epigenetic values at particular loci.
The second patent, for which the Company obtained a Notice of Allowance, leverages machine studying to estimate facets about a person’s well being, corresponding to illness states, biomarker ranges, drug use, well being histories, and components used to underwrite mortality threat. Commercial functions for this patent could embrace a potential AI platform for the supply of well being and well-being data-driven insights to people, healthcare professionals and third-party service suppliers, life insurance coverage underwriting, medical testing, and shopper well being.
To help these patents, the Company has generated epigenetic knowledge for over 13,000 people by means of internally sponsored analysis and exterior analysis collaborations. Pairing these knowledge with broad phenotypic data is anticipated to assist drive product growth as demonstrated in the Company’s patent claims.
Mark White, Interim CEO of FOXO Technologies, said, “As a pioneer in epigenetic biomarker discovery and commercialization, FOXO Technologies is devoted to harnessing the energy of epigenetics and synthetic intelligence to present data-driven insights that foster optimum well being and longevity for people and organizations alike. With a robust dedication to bettering the high quality of life and selling well-being, FOXO Technologies stands at the forefront of innovation in the biotechnology business, with plans to leverage AI know-how so as to broaden into extra industrial markets.”
“The newly granted patent underscores FOXO Technologies’ place as a chief in the convergence of biotechnology and synthetic intelligence. It represents a vital milestone in the Company’s mission to prolong and improve human life by means of superior diagnostics, therapeutic options, and way of life modifications. Moreover, by combining the fields of epigenetics and synthetic intelligence, FOXO Technologies’ pioneering method units a new customary for personalised healthcare. This patent represents a vital step ahead in growing progressive instruments that empower people and healthcare professionals to make knowledgeable choices about well being and well-being.”
Nichole Rigby, Director of Bioinformatics & Data Science at FOXO Technologies, additional famous, “The granting of these patents reaffirms our dedication to pushing the boundaries to convey collectively biotechnology and AI. We eagerly anticipate the transformative influence of this know-how on well being options, paving the approach for more healthy and longer lives for everybody.”
About FOXO Technologies Inc. (“FOXO”)
FOXO, a know-how platform firm, is a chief in epigenetic biomarker discovery and commercialization targeted on commercializing longevity science by means of services that serve a number of industries. FOXO’s epigenetic know-how applies AI to DNA methylation to establish molecular biomarkers of human well being and growing older. For extra details about FOXO, go to For investor data and updates, go to
Forward-Looking Statements
This press launch accommodates sure forward-looking statements for functions of the “protected harbor” provisions below the United States Private Securities Litigation Reform Act of 1995. Any statements apart from statements of historic reality contained herein, together with statements as to future outcomes of operations and monetary place, deliberate services, enterprise technique and plans, targets of administration for future operations of FOXO, market dimension and progress alternatives, aggressive place and technological and market traits, are forward-looking statements. Such forward-looking statements embrace, however not restricted to, expectations, hopes, beliefs, intentions, plans, prospects, monetary outcomes or methods relating to FOXO; the future monetary situation and efficiency of FOXO and the merchandise and markets and anticipated future efficiency and market alternatives of FOXO. These forward-looking statements usually are recognized by the phrases “anticipate,” “imagine,” “may,” “count on,” “estimate,” “future,” “intend,” “technique,” “could,” “may,” “technique,” “alternative,” “plan,” challenge,” “doable,” “potential,” “challenge,” “predict,” “scales,” “consultant of,” “valuation,” “ought to,” “will,” “would,” “shall be,” “will proceed,” “will doubtless consequence,” and comparable expressions, however the absence of these phrases doesn’t imply that a assertion isn’t forward-looking. Forward-looking statements are predictions, projections and different statements about future occasions which can be based mostly on present expectations and assumptions and, as a consequence, are topic to dangers and uncertainties. Many components may trigger precise future occasions to differ materially from the forward-looking statements on this press launch, together with however not restricted to: (i) the threat of modifications in the aggressive and extremely regulated industries through which FOXO operates, variations in working efficiency throughout opponents or modifications in legal guidelines and laws affecting FOXO’s enterprise; (ii) the capacity to implement FOXO’s enterprise plans, forecasts, and different expectations; (iii) the capacity to receive financing if wanted; (iv) the capacity to keep its NYSE American itemizing; (v) the threat that FOXO has a historical past of losses and should not obtain or keep profitability in the future; (vi) potential lack of ability of FOXO to set up or keep relationships required to advance its objectives or to obtain its commercialization and growth plans; (vii) the enforceability of FOXO’s mental property, together with its patents and the potential infringement on the mental property rights of others; and (viii) the threat of downturns and a altering regulatory panorama in the extremely aggressive biotechnology business or in the markets or industries through which FOXO’s potential clients function. The foregoing checklist of components isn’t exhaustive. Readers ought to rigorously contemplate the foregoing components and the different dangers and uncertainties mentioned in FOXO’s most up-to-date studies on Forms 10-Ok and 10-Q, significantly the “Risk Factors” sections of these studies, and in different paperwork FOXO has filed, or will file, with the SEC. These filings establish and deal with different necessary dangers and uncertainties that would trigger precise occasions and outcomes to differ materially from these contained in the forward-looking statements. Forward-looking statements converse solely as of the date they’re made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and doesn’t intend to replace or revise these forward-looking statements, whether or not as a consequence of new data, future occasions, or in any other case. Contacts
Crescendo Communications, LLC
(212) 671-1020
[email protected]

Recommended For You